Alnylam completes enrolment in Phase II Transthyretin-Mediated Amyloidosis clinical trial

Alnylam Pharmaceuticals has completed enrolment in its Phase II trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news